Abstract:Atopic dermatitis (AD) is a common, chronic and relapsing inflammatory skin disease with various clinical presentations and combinations of symptoms. The pathophysiology of AD is complex and multifactorial. There are several factors involved in the etiopathogenesis of AD including structural and immunological epidermal barrier defect, imbalance of the skin microbiome, genetic background and environmental factors. Alterations in structural proteins, lipids, proteases, and their inhibitors, lead to the impairment of the stratum corneum which is associated with the increased skin penetration and transepidermal water loss. The elevated serum immunoglobulin E levels and blood eosinophilia have been shown in the majority of AD patients. Type 2 T-helper cell immune pathway with increased expression of interleukin (IL)-4, IL-5, and IL-13, has an important role in the etiopathogenesis of AD. Both T cells and keratinocytes contribute to epidermal barrier impairment in AD via a dynamic interaction of cytokines and chemokines. The skin microbiome is another factor of relevance in the etiopathogenesis of AD. It has been shown that during AD flares, Staphylococcus aureus ( S. aureus ) colonization increased, while Staphylococcus epidermidis ( S. epidermidis ) decreased. On the contrary, S. epidermidis and species of Streptococcus , Corynebacterium and Propionibacterium increased during the remision phases. However, it is not clear whether skin dysbiosis is one of the symptoms or one of the causes of AD. There are several therapeutic options, targeting these pathways which play a critical role in the etiopathogenesis of AD. Although topical steroids are the mainstay of the treatment of AD, new biological therapies including IL-4, IL-13, and IL-31 inhibitors, as well as Janus kinase inhibitors (JAKi), increasingly gain more importance with new advances in the therapy of AD. In this review, we summarize the role of immunological and structural epidermal barrier dysfunction, immune abnormalities, impairment of lipids, filaggrin mutation and skin microbiome in the etiopathogenesis of AD, as well as the therapeutic options for AD and their effects on these abnormalities in AD skin.

Update on the pathogenesis of atopic dermatitis

Update on the Pathogenesis and Therapy of Atopic Dermatitis

The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update

Updates in atopic dermatitis for the primary care physician: A review of advances in the understanding and treatment of atopic dermatitis

Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options

Recent Advancements in the Atopic Dermatitis Mechanism

Patho‐immunological mechanisms of atopic dermatitis: The role of the three major human microbiomes

Understanding the Pathophysiology of Atopic Dermatitis – insights into Immune Dysregulation and Skin Barrier Dysfunction

Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies

Atopic dermatitis: a brief review of recent advances in management

Profile of skin barrier proteins and cytokines in adults with atopic dermatitis

Pathophysiology of atopic dermatitis: Clinical implications.

Molecular Biology of Atopic Dermatitis

Molecular Mechanisms of Atopic Dermatitis Pathogenesis

Cellular and molecular mechanisms in atopic dermatitis

Deciphering epigenetic regulations in the inflammatory pathways of atopic dermatitis

The Interaction between the Host Genome, Epigenome, and the Gut–Skin Axis Microbiome in Atopic Dermatitis

Advances of the exposome at individual levels and prevention in atopic dermatitis

Targeting the Gut Microbiome for Atopic Dermatitis: A Comprehensive Review of Mechanisms and Therapeutic Approaches

Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches